Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Publication of AR053738A1publicationCriticalpatent/AR053738A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Una formulacion util para el tratamiento de hepatitis C (VHC). También se describen métodos para tratar el VHC usando las formulaciones y procesos para hacer las formulaciones. Reivindicacion 1: Una formulacion farmacéutica caracteriza porque comprende TPS y un compuesto de la formula (1), en donde: n es 1 o 2; y X se selecciona de hidrogeno, Li, Na, K, Mg, y Ca; con la condicion de que cuando n es 1, X se selecciona de hidrogeno, Li, Na, y K cuando n es 2, X se selecciona de Mg y Ca.A useful formulation for the treatment of hepatitis C (HCV). Methods for treating HCV using formulations and processes to make formulations are also described. Claim 1: A pharmaceutical formulation characterized in that it comprises TPS and a compound of the formula (1), wherein: n is 1 or 2; and X is selected from hydrogen, Li, Na, K, Mg, and Ca; with the proviso that when n is 1, X is selected from hydrogen, Li, Na, and K when n is 2, X is selected from Mg and Ca.
ARP060102173A2005-05-262006-05-24
PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF HEPATITIS C
AR053738A1
(en)
Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.